Sales & Marketing News | pharmaphorum

News

Lawsuit claims J&J illegally delayed Stelara biosimilars

A lawsuit in the US is accusing Johnson & Johnson of unlawfully delaying the onset of biosimilar competition to its immunology blockbuster Stelara beyond its US patent

News

Roche bolsters diagnostics with $295m LumiraDx deal

A flurry of mergers and acquisitions in the pharma space at the end of 2023 ended with a $295 million deal by Roche to buy a point-of-care diagnostics platform from Lumira

News

Update: Apple Watches back on sale after appeal

Apple has resumed the sale of some of its smartwatches in the US, after filing an emergency appeal against a decision by the Biden administration not to veto a ban on impo

News

BMS wagers $14bn on Karuna’s schizophrenia drug

Bristol-Myers Squibb has decided to gamble on the FDA approving Karuna Therapeutics’ schizophrenia drug candidate KarXT next year, agreeing to buy the company for approxim

News

FDA approves Ionis, AZ’s Wainua for ATTR polyneuropathy

AstraZeneca and Ionis are planning a US launch next month for Wainua, their treatment for polyneuropathy in life-threatening disease transthyretin-mediated amyloidosis (AT

News

Servier facing €431m penalties in new Mediator judgment

The Paris Court of Appeals has handed down its judgment against Servier in the case involving its weight-loss therapy mediator, finding the company guilty of fraud and ord

Lawsuit claims J&J illegally delayed Stelara biosimilars

Roche bolsters diagnostics with $295m LumiraDx deal

Update: Apple Watches back on sale after appeal

BMS wagers $14bn on Karuna’s schizophrenia drug

FDA approves Ionis, AZ’s Wainua for ATTR polyneuropathy

Servier facing €431m penalties in new Mediator judgment

LSX2026: Addressing adult eye cancer, with Roi Raz

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks